InsiderTrades.com logo
Man behind OpenAI makes shocking new bet
From DTI   |   Ad
Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.
Check out our report right here.

CDT Insider Trading

Insider Ownership Percentage: 34.74%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,447,018.19

Conduit Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Conduit Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Conduit Pharmaceuticals Share Price & Price History

Current Price: $0.11
Price Change: ▲ Price Increase of +0.0213 (23.08%)
As of 11/21/2024 01:05 PM ET

This chart shows the closing price history over time for CDT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
From Colonial Metals   |   Ad
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Claim your FREE 2024 Gold Guide

Conduit Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2024Ltd NirlandMajor ShareholderSell939,009$0.10$93,900.906,092,000View SEC Filing Icon  
10/4/2024Ltd NirlandMajor ShareholderSell1,368,991$0.10$136,899.107,031,009View SEC Filing Icon  
10/2/2024Ltd NirlandMajor ShareholderSell333,177$0.10$33,317.709,900,000View SEC Filing Icon  
9/30/2024Ltd NirlandMajor ShareholderSell1,016,823$0.12$122,018.7611,483,177View SEC Filing Icon  
7/17/2024Andrew ReganDirectorSell1,514,100$0.26$393,666.00177,627View SEC Filing Icon  
7/15/2024Andrew ReganDirectorSell1,005,200$0.25$251,300.0011,936,119View SEC Filing Icon  
7/12/2024Andrew ReganDirectorSell1,389,820$0.25$347,455.0012,941,319View SEC Filing Icon  
7/10/2024Andrew ReganDirectorSell150,000$0.33$49,500.0015,214,091View SEC Filing Icon  
7/8/2024Andrew ReganDirectorSell35,923$0.51$18,320.7315,441,772View SEC Filing Icon  
7/3/2024Andrew ReganDirectorSell1,000$0.64$640.0015,477,695View SEC Filing Icon  
See Full Table
Tesla Execs are Freaking Out
From Angel Publishing   |   Ad
It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.
Click here to get the details.

SEC Filings (Institutional Ownership Changes) for Conduit Pharmaceuticals (NASDAQ:CDT)

3.29% of Conduit Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Conduit Pharmaceuticals logo
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Read More on Conduit Pharmaceuticals

Today's Range

Now: $0.11
Low: $0.11
High: $0.16

50 Day Range

MA: $0.11
Low: $0.09
High: $0.14

52 Week Range

Now: $0.11
Low: $0.08
High: $7.83

Volume

507,638,219 shs

Average Volume

9,162,864 shs

Market Capitalization

$10.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Who are the company insiders with the largest holdings of Conduit Pharmaceuticals?

Conduit Pharmaceuticals' top insider investors include:
  1. Andrew Regan (Director)
  2. Ltd Nirland (Major Shareholder)
Learn More about top insider investors at Conduit Pharmaceuticals.
This Bull Market Indicator called NVDA at $116
From WealthPress   |   Ad
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
All you have to do is follow this link here